Decentralized Clinical Trials Among Topics Slated For CDER Guidance In 2020
Executive Summary
US FDA's to-do list also includes guidances on development of non-opioid analgesics and cannabis compounds, evaluation of generic therapeutic equivalence, and pediatric product development.
You may also be interested in...
Orphan Exclusivity For Gene Therapies Hinges On Two Big Factors
US FDA draft guidance says that ‘minor differences’ in transgenes and/or vectors won’t be enough for orphan exclusivity, but agency will consider ‘additional features of the final product’ in making the determination.
US FDA's Decade In Review: From Biosimilars To Real-World Evidence
A look back over FDA actions during the past 10 years shows the evolution of its policies on opioids, preemption, off-label promotion and use of real-world evidence.
Pediatric Studies: Industry Seeks Narrower, More Timely Requests From US FDA
PhRMA asks FDA to consider expiration of pediatric exclusivity in requesting pediatric clinical trials; AbbVie describes eight-year effort to begin enrollment in Humira pediatric ulcerative colitis study.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
